Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01569737 · ClinicalTrials.gov registry record
Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
A clinical trial, sponsored by HRA Pharma.
- Completed
- Registry status
- 98
- Enrollment target
NCT01569737: Completed study, sponsored by HRA Pharma.
NCT01569737 is a clinical trial that has completed, run by HRA Pharma. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01569737 has completed, sponsored by HRA Pharma.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies exposed to ella, whether due to failure of the emergency contraception or inadvertent exposure during pregnancy.
Primary Outcome
Live birth outcomes: Healthy baby; Congenital anomaly: a baby born with a congenital anomaly; Neonatal death: a newborn who died during the first 28 days of life; Preterm birth: a baby born at less than 37 weeks of gestational age; Pregnancy loss outcomes: Ectopic pregnancy: implantation of the fertilized egg and pregnancy development in a location outside the uterus and attempt to develop in this location; Spontaneous abortion: early fetal death (i.e. less than 20 completed weeks of gestatio
Interventions
- DRUG ella
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2014-11-18 |
| Est. Completion | 2018-06-29 |
What the finished NCT01569737 record still lists
NCT01569737 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ella is the first listed.
NCT01569737 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01569737 about?
NCT01569737 is a clinical study titled "Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella". The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies exposed to ella, whether due to failure of the emergency contraception or inadvertent exposure during pregnancy.
What is the current status of trial NCT01569737?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2014-11-18. Estimated completion is 2018-06-29.
What interventions are being tested in trial NCT01569737?
The interventions under investigation include: ella (DRUG).
Who is sponsoring clinical trial NCT01569737?
This trial is sponsored by HRA Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI